Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 4/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | QPCT | Q16769 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31421606 | 1.00 | TBXAS1 (0.54) | TBXAS1L3MBTL1TDP1QPCTMEN1 | |
| SCHEMBL4781044 | 0.95 | L3MBTL1 (0.60) | L3MBTL1QPCTMEN1KMT2ALMNA | |
| Acetic Acid SCHEMBL28832331 | 0.91 | L3MBTL1 (0.56) | TBXAS1L3MBTL1QPCTMEN1KMT2A | |
| SCHEMBL5052775 | 0.89 | L3MBTL1 (0.49) | TBXAS1L3MBTL1QPCTMEN1KMT2A | |
| Iodide SCHEMBL2425744 | 0.87 | L3MBTL1 (0.49) | TBXAS1L3MBTL1TDP1QPCTMEN1 | |
| Butyric Acid SCHEMBL28832195 | 0.86 | TBXAS1 (0.52) | TBXAS1L3MBTL1QPCTMEN1KMT2A | |
| SCHEMBL31436074 | 0.85 | NAMPT (0.50) | L3MBTL1QPCTMEN1KMT2ALMNA | |
| SCHEMBL31421155 | 0.83 | L3MBTL1 (0.44) | TBXAS1L3MBTL1QPCTMEN1KMT2A | |
| SCHEMBL25591200 | 0.81 | L3MBTL1 (0.68) | TBXAS1L3MBTL1QPCTMEN1KMT2A | |
| SCHEMBL14701138 | 0.80 | L3MBTL1 (0.46) | L3MBTL1QPCTMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807682-B2 | Pyridyl cyanoguanidine compounds | LEO PHARMA A/S (DK) | 2010-10-05 | — | — | US | disclosed |
| EP-1397355-B1 | PYRIDYL CYANOGUANIDINE COMPOUNDS | LEO PHARMA AS (DK) | 2009-09-09 | — | — | EP | disclosed |
| US-20080090842-A1 | Novel pyridyl cyanoguanidine compounds | LEO PHARMA A/S (DK) | 2008-04-17 | — | — | US | disclosed |
| US-7304066-B2 | Pyridyl cyanoguanidine compounds | LEO PHARMA A/S (DK) | 2007-12-04 | — | — | US | disclosed |
| CN-1247570-C | Novel pyridyl cyanoguandine compounds | LEO PHARMA AS (DK) | 2006-03-29 | — | — | CN | disclosed |
| US-20040220408-A1 | Novel pyridyl cyanoguanidine compounds | LEO PHARMA A/S (DK) | 2004-11-04 | — | — | US | disclosed |
| CN-1509283-A | novel pyridyl cyanoguanidine compounds | ������ҩ������˾ | 2004-06-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220408-A1 | Novel pyridyl cyanoguanidine compounds | DAO, AOC1, SIGMAR1 | TBXAS1 2150/4885L3MBTL1 1377/4885TDP1 1132/4885 |
| US-20080090842-A1 | Novel pyridyl cyanoguanidine compounds | DAO, CCNY, CBR1 | TBXAS1 970/4885L3MBTL1 1834/4885TDP1 1835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.